SLS Stock Price, SELLAS Life Sciences Group Quote, Chart

Market Summary

USD1.35+0.02

Market Closed

1.50%

SLS Stock Price

View Fullscreen

SLS RSI Chart

SLS Valuation

Market Cap

76.0M

Price/Earnings (Trailing)

-2.03

Price/Sales (Trailing)

32.45

EV/EBITDA

-0.73

Price/Free Cashflow

-2.42

SLS Price/Sales (Trailing)

SLS Profitability

Operating Margin

-58.60%

EBT Margin

-4130.10%

Return on Equity

468.15%

Return on Assets

-600.42%

Free Cashflow Yield

-41.34%

SLS Fundamentals

SLS Revenue

SLS Earnings

Earnings (TTM)

-37.3M

Earnings Growth (Yr)

10.8%

Earnings Growth (Qtr)

12.2%

Breaking Down SLS Revenue

Last 7 days

-3.6%

Last 30 days

22.7%

Last 90 days

159.6%

Trailing 12 Months

-18.7%

How does SLS drawdown profile look like?

SLS Financial Health

Current Ratio

0.23

SLS Investor Care

Shares Dilution (1Y)

98.49%

Diluted EPS (TTM)

-1.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	2.9M	1.0M	1.0M	1.0M
2021	3.3M	4.8M	6.2M	7.6M
2020	0	0	0	1.9M
2015	9.9M	10.9M	0	0
2014	9.3M	9.3M	9.3M	9.3M
2013	0	7.0M	7.4M	9.3M
2012	0	0	0	0
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of SELLAS Life Sciences Group Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 22, 2024	kalin katherine bach	acquired	-	-	6,000	-
Jan 22, 2024	francomano robert	acquired	-	-	20,000	chief commercial officer
Jan 22, 2024	stergiou angelos m.	acquired	-	-	159,000	president and ceo
Jan 22, 2024	burns john thomas	acquired	-	-	47,000	cfo
Jan 22, 2024	varian john	acquired	-	-	6,000	-
Jan 22, 2024	wasman jane	acquired	-	-	6,000	-
Jan 22, 2024	scheinberg david a	acquired	-	-	6,000	-
Jan 22, 2024	van nostrand robert l	acquired	-	-	6,000	-
Jan 22, 2024	wood barbara a	acquired	-	-	35,000	evp, gen. counsel, corp. sec.
Dec 06, 2023	francomano robert	sold	-1,168	1.08	-1,082	chief commercial officer

Which funds bought or sold SLS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	JANICZEK WEALTH MANAGEMENT, LLC	unchanged	-	-	12.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	10.65	-484,362	1,216,160	-%
Feb 26, 2024	Virtu Financial LLC	added	215	33,000	64,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-18,092	-	-%
Feb 14, 2024	Engineers Gate Manager LP	new	-	17,868	17,868	-%
Feb 14, 2024	Royal Bank of Canada	added	79.00	-	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	new	-	11,913	11,913	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	16,222	16,222	-%
Feb 14, 2024	Prosperity Financial Group, Inc.	sold off	-100	-40,672	-	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	44.00	44.00	-%

Are Funds Buying or Selling SLS?

Are funds buying SLS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SLS

No. of Funds

Unveiling SELLAS Life Sciences Group Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	highbridge capital management llc	6.5%	2,080,054	SC 13G
Feb 16, 2021	cvi investments, inc.	2.7%	315,249	SC 13G/A
Feb 12, 2021	packer paul	1.2%	141,553	SC 13G/A
Dec 14, 2020	hirschman orin	1.5%	190,000	SC 13G/A
Sep 21, 2020	packer paul	5.3%	497,391	SC 13G
Aug 25, 2020	hirschman orin	9.9%	936,735	SC 13G
Feb 14, 2020	altium capital management lp	1.1%	56,000	SC 13G/A
Feb 14, 2020	anson funds management lp	-	0	SC 13G/A
Feb 13, 2020	683 capital management, llc	1%	38,000	SC 13G/A
Feb 13, 2020	renaissance technologies llc	0.00%	0	SC 13G/A

Recent SEC filings of SELLAS Life Sciences Group Inc

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	D	D
Mar 28, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	S-3	S-3
Mar 28, 2024	S-3	S-3
Mar 18, 2024	424B5	Prospectus Filed
Mar 15, 2024	8-K	Current Report
Mar 11, 2024	8-K	Current Report
Mar 08, 2024	8-K	Current Report

Peers (Alternatives to SELLAS Life Sciences Group Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	-0.04%	-27.89%	-8.41	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.5B	1.8B	-1.63%	-28.69%	-42.01	10.12	76.23%	61.08%
BMRN	17.2B	2.4B	8.39%	-9.36%	102.31	7.09	15.42%	18.43%
INCY	11.9B	3.7B	-8.82%	-29.04%	20	3.23	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-8.69%	-36.86%	-11.82	15.75	425.83%	18.94%
BBIO	4.4B	-	-8.20%	68.33%	-6.81	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-8.92%	-2.36%	-13.62	12.04	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.30%	-24.47%	-9.88	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-11.77%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.36%	-14.10%	25.63	4.6	85.90%	-14.05%
NVAX	557.0M	983.7M	-24.76%	-57.93%	-1.02	0.57	-50.36%	17.16%
CRBP	432.8M	881.7K	-5.56%	294.36%	-9.7	466.16	-77.61%	-5.33%
INO	225.3M	4.9M	-10.24%	-14.54%	-1.67	46.29	-54.97%	51.72%
IBIO	6.8M	2.1M	86.67%	92.16%	-0.25	2.14	-13.45%	66.37%

SELLAS Life Sciences Group Inc News

Latest updates

SELLAS Life Sciences Group Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4
Revenue	-	-	-	-	-	1,000,000	-	-	1,900,000	5,700,000	4,541,000	3,382,000	2,750,000	3,195,000	1,620,000	2,331,000	2,173,000	3,195,000	1,620,000	2,331,000	2,173,000	1,317,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	468,000	393,000	478,000	247,000	347,000	331,000	262,000	258,000	-	-	-
Costs and Expenses	-13.4%	8,177,000	9,446,000	7,146,000	8,623,000	17,735,000	11,619,000	6,977,000	6,353,000	7,945,000	6,059,000	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,130,000	7,762,000	7,986,000	6,611,000	5,578,000
S&GA Expenses	-14.4%	3,080,000	3,600,000	2,864,000	3,094,000	3,024,000	2,526,000	2,436,000	2,797,000	3,561,000	3,288,000	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-	-	-	-	-	-	3,393,000	4,541,000	3,456,000	4,284,000	2,771,000	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	0.8%	-40.67	-41.00	-20.79	-20.90	-7.22	-2.76	-2.72	-3.53	-5.05	-8.82	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-74.1%	41,000	158,000	111,000	46,000	2,000	-	2,000	2,000	2,000	1,000	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	0%	-41.30	-41.30	-20.94	-20.94	-7.22	-2.75	-2.72	-3.53	-5.04	-8.83	-	-	-	-	-	-	-	-	-	-	-
Net Income	10.8%	-8,136,000	-9,121,000	-7,022,000	-8,414,000	-16,744,000	-6,598,000	-7,085,000	-4,613,000	-2,403,000	-3,716,000	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	9.6%	-37.34	-41.30	-38.78	-38.84	-12.08	-2.72	-2.89	-3.20	-4.52	-8.82	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	6.4%	-4,815,000	-5,143,000	-5,746,000	-5,761,000	-7,150,000	-4,976,000	-5,878,000	-4,898,000	-10,269,000	3,424,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-23.1%	6.00	8.00	19.00	29.00	21.00	26.00	32.00	21.00	26.00	38.00	44.00	41.00	46.00	19.00	15.00	17.00	17.00	21.00	25.00	15.00	17.00
Current Assets	-39.0%	3.00	5.00	16.00	26.00	18.00	23.00	29.00	18.00	23.00	29.00	35.00	31.00	37.00	9.00	5.00	9.00	8.00	10.00	14.00	3.00	6.00
Cash Equivalents	-36.3%	3.00	4.00	14.00	24.00	17.00	21.00	27.00	14.00	21.00	26.00	30.00	28.00	35.00	8.00	3.00	7.00	7.00	9.00	13.00	3.00	5.00
Goodwill	-0.7%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	19.2%	14.00	12.00	14.00	16.00	16.00	13.00	13.00	17.00	6.00	11.00	10.00	12.00	18.00	11.00	11.00	9.00	11.00	11.00	11.00	12.00	12.00
Current Liabilities	17.0%	14.00	12.00	13.00	16.00	16.00	13.00	12.00	11.00	5.00	5.00	4.00	6.00	12.00	4.00	4.00	4.00	5.00	6.00	5.00	6.00	6.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-7.98	-	5.00	13.00	5.00	13.00	19.00	4.00	20.00	27.00	33.00	29.00	28.00	8.00	4.00	8.00	6.00	11.00	14.00	3.00	5.00
Retained Earnings	-3.9%	-217	-209	-199	-191	-179	-170	-163	-155	-138	-132	-124	-120	-117	-114	-109	-105	-101	-93.73	-89.53	-86.39	-81.85
Additional Paid-In Capital	1.9%	209	205	205	204	185	183	183	159	159	159	158	149	146	122	113	113	107	104	104	89.00	87.00
Shares Outstanding	13.2%	32.00	28.00	28.00	28.00	21.00	19.00	18.00	16.00	16.00	16.00	15.00	15.00	14.00	-	-	-	-	-	-	-	-
Float	-	-	-	44.00	-	-	-	46.00	-	-	-	176	-	-	-	20.00	-	-	-	11.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	30.0%	-4,825	-6,892	-7,593	-12,100	-5,152	-5,746	-5,761	-7,150	-4,976	-5,878	-4,898	-10,269	3,424	-3,629	-3,381	-6,831	-4,176	-3,820	-4,656	-4,991	-4,555
Share Based Compensation	-8.5%	497	543	514	540	446	455	450	375	288	275	264	184	141	146	146	145	147	115	126	185	111
Cashflow From Investing	100.0%	-	-3,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	6170.4%	3,386	54.00	-29.00	18,904	929	107	22,996	47.00	50.00	2,242	6,782	3,000	23,675	8,492	-25.00	6,300	2,319	189	14,831	2,230	-76.00
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

SLS Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Licensing revenue	$ 0	$ 1,000,000
Operating expenses:
Cost of licensing revenue	0	100,000
Research and development	24,007,000	20,268,000
General and administrative	13,862,000	12,582,000
Acquired in-process research and development	0	10,000,000
Total operating expenses	37,869,000	42,950,000
Loss from operations	(37,869,000)	(41,950,000)
Non-operating income:
Change in fair value of warrant liability	4,000	36,000
Change in fair value of contingent consideration	0	296,000
Interest income	525,000	317,000
Total non-operating income	529,000	649,000
Net loss	$ (37,340,000)	$ (41,301,000)
Per share information:
Net loss per common share, basic (in dollars per share)	$ (1.34)	$ (2.13)
Net loss per common share, diluted (in dollars per share)	$ (1.34)	$ (2.13)
Weighted-average common shares outstanding, basic (in shares)	27,777,111	19,395,709
Weighted-average common shares outstanding, diluted (in shares)	27,777,111	19,395,709

SLS Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,530	$ 17,125
Restricted cash and cash equivalents	100	100
Prepaid expenses and other current assets	542	531
Total current assets	3,172	17,756
Operating lease right-of-use assets	858	874
Goodwill	1,914	1,914
Deposits and other assets	275	399
Total assets	6,219	20,943
Current liabilities:
Accounts payable	5,639	3,357
Accrued expenses and other current liabilities	7,650	6,286
Operating lease liabilities	446	372
Acquired in-process research and development payable	0	5,500
Total current liabilities	13,735	15,515
Operating lease liabilities, non-current	460	573
Warrant liability	0	4
Total liabilities	14,195	16,092
Commitments and contingencies (Note 7)
Stockholders’ (deficit) equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; 0 shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 350,000,000 shares authorized, 32,132,890 and 21,005,405 shares issued and outstanding at December 31, 2023 and 2022, respectively	3	2
Additional paid-in capital	209,265	184,753
Accumulated deficit	(217,244)	(179,904)
Total stockholders’ (deficit) equity	(7,976)	4,851
Total liabilities and stockholders’ (deficit) equity	$ 6,219	$ 20,943

About SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

CEO	Dr. Angelos M. Stergiou M.D., ScD h.c.
WEBSITE	sellaslifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	17

SELLAS Life Sciences Group Inc Frequently Asked Questions

What is the ticker symbol for SELLAS Life Sciences Group Inc? What does SLS stand for in stocks?

SLS is the stock ticker symbol of SELLAS Life Sciences Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SELLAS Life Sciences Group Inc (SLS)?

As of Tue Apr 16 2024, market cap of SELLAS Life Sciences Group Inc is 75.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLS stock?

You can check SLS's fair value in chart for subscribers.

What is the fair value of SLS stock?

You can check SLS's fair value in chart for subscribers. The fair value of SELLAS Life Sciences Group Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SELLAS Life Sciences Group Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SLS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SELLAS Life Sciences Group Inc a good stock to buy?

The fair value guage provides a quick view whether SLS is over valued or under valued. Whether SELLAS Life Sciences Group Inc is cheap or expensive depends on the assumptions which impact SELLAS Life Sciences Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLS.

What is SELLAS Life Sciences Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, SLS's PE ratio (Price to Earnings) is -2.03 and Price to Sales (PS) ratio is 32.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on SELLAS Life Sciences Group Inc's stock?

In the past 10 years, SELLAS Life Sciences Group Inc has provided -0.653 (multiply by 100 for percentage) rate of return.